JP2023504734A - 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法 - Google Patents

制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法 Download PDF

Info

Publication number
JP2023504734A
JP2023504734A JP2022534147A JP2022534147A JP2023504734A JP 2023504734 A JP2023504734 A JP 2023504734A JP 2022534147 A JP2022534147 A JP 2022534147A JP 2022534147 A JP2022534147 A JP 2022534147A JP 2023504734 A JP2023504734 A JP 2023504734A
Authority
JP
Japan
Prior art keywords
tregs
cryopreserved
expanded
population
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504734A5 (enExample
Inventor
ハーシュ アペル スタンレー
ロバート ソンホフ ジェイソン
ロバート ビアーズ デイビッド
ドリュー ゾーメ アーロン
Original Assignee
ザ メソディスト ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ メソディスト ホスピタル filed Critical ザ メソディスト ホスピタル
Publication of JP2023504734A publication Critical patent/JP2023504734A/ja
Publication of JP2023504734A5 publication Critical patent/JP2023504734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2022534147A 2019-12-05 2020-12-04 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法 Pending JP2023504734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944346P 2019-12-05 2019-12-05
US62/944,346 2019-12-05
PCT/US2020/063378 WO2021113685A2 (en) 2019-12-05 2020-12-04 Regulatory t cell (treg) compositions and methods for treating neurodegenerative disease

Publications (2)

Publication Number Publication Date
JP2023504734A true JP2023504734A (ja) 2023-02-06
JP2023504734A5 JP2023504734A5 (enExample) 2024-02-14

Family

ID=74104193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534147A Pending JP2023504734A (ja) 2019-12-05 2020-12-04 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法

Country Status (7)

Country Link
US (1) US20230047159A1 (enExample)
EP (1) EP4069259A2 (enExample)
JP (1) JP2023504734A (enExample)
AU (1) AU2020397893A1 (enExample)
CA (1) CA3159411A1 (enExample)
MX (1) MX2022006674A (enExample)
WO (1) WO2021113685A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221900A1 (en) * 2021-06-08 2022-12-15 Stanley Hersh Appel Methods for producing regulatory t cell (treg) populations, treg compositions and methods for treatment
WO2024233788A2 (en) * 2023-05-09 2024-11-14 The Mclean Hospital Corporation Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122945A1 (ja) * 2009-04-24 2010-10-28 株式会社林原生物化学研究所 細胞障害活性及び免疫抑制活性を併せ持つヒトｔ細胞集団の製造方法
WO2017218533A1 (en) * 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122945A1 (ja) * 2009-04-24 2010-10-28 株式会社林原生物化学研究所 細胞障害活性及び免疫抑制活性を併せ持つヒトｔ細胞集団の製造方法
WO2017218533A1 (en) * 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRONT. IMMUNOL., vol. 10, JPN6025006352, February 2019 (2019-02-01), pages 38 - 1, ISSN: 0005743098 *
HUM. IMMUNOL., vol. vol.66, issue 3, JPN6025006353, 2005, pages 222 - 230, ISSN: 0005743099 *
MOL. THER. METHODS CLIN. DEV., vol. 8, JPN6025006350, 2018, pages 198 - 209, ISSN: 0005743096 *
ONCOTARGET, vol. 7, no. 7, JPN6025006349, 2016, pages 7563 - 7577, ISSN: 0005743095 *
TRANSPLANTATION, vol. 95, no. 11, JPN6025006351, 2013, pages 68 - 70, ISSN: 0005743097 *

Also Published As

Publication number Publication date
MX2022006674A (es) 2022-11-14
US20230047159A1 (en) 2023-02-16
AU2020397893A1 (en) 2022-06-09
CA3159411A1 (en) 2021-06-10
WO2021113685A3 (en) 2021-07-08
WO2021113685A2 (en) 2021-06-10
EP4069259A2 (en) 2022-10-12
AU2020397893A8 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
Ochando et al. Trained immunity—basic concepts and contributions to immunopathology
JP6987945B2 (ja) ヒトメソテリンキメラ抗原受容体およびその使用
KR102686794B1 (ko) 종양 침윤 림프구의 제조 방법 및 면역요법에서의 그의 용도
AU2016250570A1 (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
JP6449148B2 (ja) 免疫抑制細胞作成方法、及び、免疫抑制細胞を含む組成物の使用方法
US20220273712A1 (en) Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy
Chang et al. Single-cell transcriptomic identified HIF1A as a target for attenuating acute rejection after heart transplantation
Pujadas et al. The gut hormone receptor GIPR links energy availability to the control of hematopoiesis
AU2020400079A1 (en) Method for obtaining nucleic acid for sequencing
JP2023504734A (ja) 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法
KR20220034041A (ko) T 세포 탈진을 치료하기 위한 조성물 및 방법
CN111886338A (zh) Crispr相关蛋白反应性t细胞免疫
US20230270781A1 (en) Treatment or prevention of pro-inflammatory diseases or conditions using induced regulatory t (itreg) cells
US20210030809A1 (en) Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
JP2023521671A (ja) Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法
US20240093150A1 (en) Improved t-cells for cancer therapy using amino acid starvation pathways
Chan Investigating the Effects of Polarized Monocytes/Macrophages in Osteoarthritis
Li et al. An in vivo MAIT cell activation and rejuvenation system for liver cancer therapy
WO2026088096A1 (en) Treatment of systemic sclerosis using a population of cd19 car-expressing cells
Schlaweck et al. The CCR4/CCL17 axis drives intestinal acute Graft versus Host disease after allogeneic bone marrow transplantation
US20210324057A1 (en) Methods and compositions for treating and preventing t cell-driven diseases
WO2024097793A1 (en) Method for manufacturing therapeutic immune cells
WO2024098072A9 (en) Implications of cxcr3 expression on myeloid cells for immunotherapy of cancer and myeloid-mediated diseases
WO2023237754A2 (en) Cyclosporin h and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202